Cytokinetics Announces Opening of Second Cohort in Phase IIb Clinical Trial of Intravenous Omecamtiv Mecarbil in Patients with Acute Heart Failure Full Text
Cytokinetics, 05/25/2012
Cytokinetics, Incorporated announced the opening to enrollment of the second cohort in the ongoing, international, randomized, double–blind, placebo–controlled Phase IIb clinical trial of an intravenous formulation of omecamtiv mecarbil, known as ATOMIC–AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure). Following a review of the data from the first cohort in this ongoing Phase IIb clinical trial, the independent data monitoring committee concluded that the current safety data supports progression to the second cohort of this trial. Amgen holds an exclusive, worldwide license (excluding Japan) to omecamtiv mecarbil and related compounds, subject to Cytokinetics’ specified development and commercialization participation rights.



